How InSilico-Con Is Using Algorithmic Magic to Reinvent the Thought Leadership Grift
Barnaby Buzzword
Self-Certified Synergist | Keynote Vapourware Evangelist | Top 0.0001% LinkedIn Noise-Polluter | “Buy My PDF or the Future Will Eat You Alive”
Thank you for consuming my latest mandatory content dump. Here at LinkedIn and The Daily Capitalism, I regularly regurgitate press releases as profound strategic foresight.
To ensure you never miss a single drop of my relentless intellectual spam, simply hit ‘Follow’, subscribe to my twelve identical newsletters, smash that notification bell, follow my TikTok, and pray for the sweet release of death.
The Infinite Money Glitch
Inventing new pills has always been a complete drag for big business. It takes a decade, costs two billion quid, and half the time the clinical trial just ends up giving laboratory beagles severe indigestion.
Enter Ex-Cello Medico, a company that claims its bespoke algorithms can bypass all that tedious science stuff by using generative magic to hallucinate new treatments out of thin air.
They’ve already achieved the ultimate corporate miracle: taking an algorithmically generated chemical molecule and pushing it through a Phase 2 trial without the whole thing immediately turning into a Netflix true-crime documentary. The entire process took under 18 months! How? By using Molecule99, an automated digital dice-roller that spat out 78,000 theoretical compounds, discarded 77,940 of them as toxic nonsense, and left 60 that didn’t immediately melt the digital test tube.
Naturally, one successful experiment isn’t enough to justify a tech valuation that rivals small nation-states. So they built an entire automated ecosystem called Pharma-Bodge.AI, supplemented by PandaPaws, an autonomous digital assistant designed to execute complex biological tasks with almost zero human oversight.
Because if there’s one thing we’ve learned from the history of science, it’s that removing humans from the loop when designing experimental bio-chemistry always ends brilliantly.
Renting Out the Digital Snake Oil
Now, even with all this automated wizardry, one tiny startup can only invent so many overpriced remedies before the legal department faints. So Ex-Cello did what any self-respecting tech firm does: they rented the software to their competitors.
Today, 13 of the world’s top 20 mega-pharma cartels are using this exact platform to generate candidate compounds for everything from mild male-pattern baldness to existential dread.
Why let your bitter rivals use your proprietary magic wand? Simple: why bother doing the hard work of curing diseases yourself when you can just become the landlord of the lab? It’s the Amazon model—don’t mine for gold, just own the shovel, charge a 30% subscription fee on the shovel, and sell advertising space on the handle.
What Can We Learn from This (Besides How to Monetize Hype)?
- Find a problem, slap ‘AI’ on it, and charge a monthly fee.
- When your internal tool works once, stop doing research and start selling software licenses.
- Pivoting from “doing science” to “owning the digital infrastructure of science” is how you turn a modest laboratory into an unregulated monopoly.
For forward-thinking disruptors, the real takeaway is simple: locate a complex human endeavor, claim a computer can do it faster, package the software into an subscription-based SaaS model, and let the legacy players pay you for the privilege of automating their own eventual irrelevance.
About Barnaby Buzzword Barnaby Buzzword is an internationally unaccredited futurist, thought-harasser, and professional slide-deck sculptor. He has published 47 books containing the exact same three chapters shuffled in different orders. He enjoys long walks on the beach and explaining basic cloud storage to terrified middle-managers.
Leave a Reply